Dithranol irritation in psoriasis treatment: a study of 68 inpatients.
The irritant response of perilesional skin is a serious limitation of dithranol therapy in psoriasis. No data are available on the actual prevalence and severity of irritation during 24-h dithranol treatment in an inpatient setting. Using a retrospective analysis of 68 patients with psoriasis visiting our inpatient department for dithranol treatment, the occurrence of dithranol irritation was studied. We found a relatively high frequency of dithranol irritation. Furthermore, most irritation occurs at the start of the therapy with relatively low concentrations.
Kucharekova
M
M
Department of Dermatology, University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands. mku@sder.azm.nl
Lieffers
L
L
van de Kerkhof
P C M
PC
van der Valk
P G M
PG
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000875:Anthralin / Q000009:adverse effects* / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D000875:Anthralin